Navigation Links
Gilead Announces Presentation of Long-Term Data for Ambrisentan, a,Potential Treatment for Patients With Pulmonary Arterial,Hypertension

wn underlying cause, or it can occur secondary to diseases such as connective tissue disease, congenital heart defects, cirrhosis of the liver and HIV infection. PAH afflicts approximately 200,000 patients worldwide.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including risks related to Gilead's ability to successfully commercialize ambrisentan for PAH. For example, the FDA may not approve ambrisentan for the treatment of PAH in the United States, and marketing approval, if granted, may have significant limitations on its use. In addition, future discussions with the FDA may impact the amount of data needed and timelines for review, which may differ materially from Gilead's current projections. Further, safety and efficacy data from additional clinical studies may not warrant further development of this compound and completing our clinical studies may take longer or cost more than expected. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Annual Report on Form 10-K for the year ended December 31, 2006 and its Report on Form 10-Q for the fi
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Achievement of Primary Efficacy Endpoint in Second Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:9/19/2014)... 19, 2014  Today DePuy Synthes Companies of ... plating systems featuring its proprietary variable angle locking ... trajectory to match patient anatomy and fracture pattern ... The systems are being introduced in conjunction with ... and the International Federation of Foot & Ankle ...
(Date:9/19/2014)... 2014 The Parenteral Drug Association (PDA) is ... changes protocols. The new initiative stems ... by industry participants and regulatory authority representatives at the ... Washington, DC . Representatives of both ... the workshop. Attendees indicated openness to engaging regulators and ...
(Date:9/19/2014)... , Sept. 19, 2014 Today, iHealth Lab ... from Xiaomi Ventures, Ltd. for its first institutional round ... continue expanding iHealth,s global reach, accelerate growth and innovation, ... part of the investment, Xiaomi Ventures will join iHealth,s ... of cloud infrastructure and ecommerce. "We are ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2
... Feb. 1 Obese teenagers who,succeeded in losing weight ... their bone mineral content increase over that,period, say researchers ... because adolescence is a critical period for bone,health in ... of the journal Obesity studied 62,adolescents between the ages ...
... as part of innovative,Therapeutics Development Initiative, NEW YORK, ... do whatever it takes to speed delivery of transformative,treatments ... Fox,Foundation for Parkinson,s Research has awarded up to $3 ... push potential new PD treatments,closer to the clinic. The ...
Cached Medicine Technology:Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss 2Bone Mineral Content Continues to Increase in Obese Adolescents During Weight Loss 3Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 2Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development 3
(Date:9/21/2014)... (PRWEB) September 21, 2014 Hundreds ... move forward in Pennsylvania’s Philadelphia Court of Common ... documents, the proceeding’s next monthly meeting has been ... number 100300296) , “Our Firm is representing a ... in this litigation. We are pleased with its ...
(Date:9/21/2014)... Dallas, Texas (PRWEB) September 21, 2014 ... Administration (FDA) in 1996, GSK’s Flovent (fluticasone propionate) ... activity. It is used for the maintenance treatment ... is now available in two formulations, Diskus and ... and 2004, respectively. Flovent’s active ingredient, fluticasone propionate, ...
(Date:9/21/2014)... An experienced review website in the global market, Top10BestSEOHosting.com, ... announced that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ), GoDaddy and Bluehost ... has been a boom in websites in recent years, ... in the number of web hosting companies that offer ... VPS (Virtual Private Server) is the method of partitioning ...
(Date:9/21/2014)... 2014 C8 lawsuits move forward in ... the list of 20 possible C8 lawsuits selected ... six, reports Wright & Schulte LLC. Court records show ... 2500 C8 lawsuits filed that represent individuals who purportedly ... a result of being exposed to water contaminated by ...
(Date:9/20/2014)... Diabetes Protocol , a breakthrough new ... thousands of people learn how to naturally manage and ... prescriptions has caught the attention of Shane Michaels, prompting ... of millions of people in the U.S. today who ... and unfortunately, big pharma makes a killing just by ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Move Forward in Pennsylvania Litigation, As Court Schedules October Meeting, Bernstein Liebhard LLP Reports 4Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2
... Recovery for Many Facing Health CrisesCHICAGO, Jan. 15 Does ... challenges have found support and compassion through online communities such ... love is more than a dozen roses or candlelit dinner ... and defying the odds for survival. Just ask Lisa, ...
... information on its revamped website. AccessRx has provided tens of ... 1998. , ... (PRWEB) January 15, ... consumer information on its revamped website. AccessRx has provided tens ...
... Two radon-induced lung cancer survivors will be joined by ... Council Radon Awards Ceremony at the National Press ... the U.S. EPA, the ceremony is part of National ... and winners of the National Radon Poster Contest; but ...
... & Nephew,s Advanced Wound Management division (LSE: SN; NYSE: ... Court in the High Court of Justice of England and ... a temporary injunction prohibiting Smith & Nephew from commercializing foam ... Kingdom. The temporary injunction will remain in place until the ...
... Nationally; Many People May Not Realize They,re InfectedHARRISBURG, Pa., ... in the number of reported cases of gonorrhea and ... testing by men and women, according to the Department ... common bacterial sexually transmitted diseases is below the national ...
... with CorVel Corporation,s (Nasdaq: CRVL ) quarterly earnings release, CorVel will be ... 3rd at 11:30 am Eastern Time. , , Event: ... Dan Starck, President and CEO, ... Date: 11:30 am Eastern Time, Tuesday, ...
Cached Medicine News:Health News:More than Just a Box of Chocolates 2Health News:More than Just a Box of Chocolates 3Health News:AccessRx.com Launches Redesigned Website, Adds Content and Builds Online Community 2Health News:Radiation Victims to Rally In Washington - Demand Congressional Action to Protect Homebuyers; Organization Labels EPA's Radon Program a 'Deadly Failure' 2Health News:Radiation Victims to Rally In Washington - Demand Congressional Action to Protect Homebuyers; Organization Labels EPA's Radon Program a 'Deadly Failure' 3Health News:Smith & Nephew Advanced Wound Management Comments on Temporary Injunction in United Kingdom 2Health News:Smith & Nephew Advanced Wound Management Comments on Temporary Injunction in United Kingdom 3Health News:CorVel Corporation Announces Earnings Release Webcast 2
... Eliminate the need for makeshift, modified nebulizer ... waste time gathering parts when your patient ... to deliver the utmost in Heliox rescue ... is fast becoming the standard of care ...
... Graham-Field has been developing diverse ... 58 years. Our medical-surgical products ... for innovation, quality and customer ... include the Labtron® line of ...
... Entrainment Nebulizers deliver particulate humidity in the ... chronic secretion patients. For your convenience, Thera-Mist® ... supply of sterile water., ,The P30000N, ... of 20-50% with a total flow range ...
... For use with metered dose inhalers., ... aerosolized medication from MDI canisters. Its versatile ... a ventilator circuit, in conjunction with an ... routine, oral inhalation. ACE may also be ...
Medicine Products: